BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2724037
Number of visits today
941
Number of downloads
1994941
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Xu W, Ye C, Qing X, Liu S, Lv X, Wang W, Dong X, Zhang Y. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Mater Today Bio 2022;16:100358. [PMID: 35880099 DOI: 10.1016/j.mtbio.2022.100358] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Brar HK, Jose J, Wu Z, Sharma M. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Pharmaceutics 2022;15. [PMID: 36678688 DOI: 10.3390/pharmaceutics15010059] [Reference Citation Analysis]
2 Andreeva OE, Sorokin DV, Scherbakov AM, Shchegolev YY, Gudkova MV, Krasil’nikov MA. MicroRNA-484 / Akt axis in the regulation of breast cancer cells sensitivity to antitumor drugs. Usp mol onkol 2022;9:112-116. [DOI: 10.17650/2313-805x-2022-9-4-112-116] [Reference Citation Analysis]
3 Lee HW, Seo HS, Yeom S, Kim S, Kim CR, Park D, Park W, Choy YB, Park CG, Seo SI. Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. IJMS 2022;23:12634. [DOI: 10.3390/ijms232012634] [Reference Citation Analysis]
4 Xu W, Xu L, Jia W, Mao X, Liu S, Dong H, Zhang H, Zhang Y. Nanomaterials based on phase change materials for antibacterial application. Biomater Sci 2022. [DOI: 10.1039/d2bm01220k] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345